Inventiva (NASDAQ:IVA) Given New $14.00 Price Target at HC Wainwright

Inventiva (NASDAQ:IVA) had its target price reduced by HC Wainwright from $22.00 to $14.00 in a research note released on Thursday, Benzinga reports. They currently have a buy rating on the stock.

Separately, Stifel Nicolaus reduced their target price on Inventiva from $25.00 to $20.00 and set a buy rating for the company in a report on Thursday. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Inventiva currently has an average rating of Buy and an average target price of $16.50.

Inventiva Stock Up 2.8 %

Shares of IVA stock opened at $1.84 on Thursday. Inventiva has a 1-year low of $1.53 and a 1-year high of $4.75. The stock has a 50 day simple moving average of $2.25 and a 200-day simple moving average of $2.96.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Inventiva stock. Virtu Financial LLC acquired a new stake in Inventiva S.A. (NASDAQ:IVA) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,490 shares of the company’s stock, valued at approximately $38,000. 19.06% of the stock is owned by institutional investors.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.